MCAD deficiency is the most common fatty acid oxidation disorder, but it is the only one without a treatment. Patients face continued risks of becoming hypoglycemic with fasting or illness, with chronic muscle symptoms becoming increasingly recognized. This webinar will present insight into metabolic changes caused by MCAD deficiency, and two clinical trials are currently open to test new medications to treat it.
